Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342912 | 0.89 | MAP2K1 (0.40) | L3MBTL1MAP2K1MEN1KMT2ASORT1 | |
| SCHEMBL3979835 | 0.88 | MAP2K1 (0.50) | L3MBTL1MAP2K1MAPTGAATHRB | |
| SCHEMBL3974682 | 0.88 | MAP2K1 (0.53) | MAP2K1KDM4E | |
| SCHEMBL3971678 | 0.84 | MAP2K1 (0.41) | L3MBTL1MAP2K1MEN1KMT2ASORT1 | |
| SCHEMBL14500090 | 0.83 | MAP2K1 (0.56) | MAP2K1CYP2C9CYP2C19ABCB11 | |
| SCHEMBL14499986 | 0.82 | IRAK4 (0.41) | L3MBTL1MAP2K1MEN1KMT2ARAB9A | |
| SCHEMBL3979053 | 0.82 | L3MBTL1 (0.39) | L3MBTL1MAP2K1MAPTGAAMEN1 | |
| SCHEMBL3971565 | 0.81 | SRC (0.44) | MAP2K1MAPTGAAKDM4EFTO | |
| SCHEMBL14499784 | 0.80 | MAP2K1 (0.51) | L3MBTL1MAP2K1MAPTKDM4ECYP1A2 | |
| SCHEMBL1343797 | 0.80 | MAP2K1 (0.39) | L3MBTL1MAP2K1MAPTGAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | L3MBTL1 1497/4885MAP2K1 92/4885MAPT 4838/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | L3MBTL1 3271/4885MAP2K1 4674/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.